142 related articles for article (PubMed ID: 37097650)
1. Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment.
Fukuda S; Niisato Y; Tsuji M; Fukuda S; Hagiwara Y; Onoda T; Suzuki H; Tange Y; Yamada T; Yamamoto Y; Moriwaki T
Anticancer Res; 2023 May; 43(5):2085-2090. PubMed ID: 37097650
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer.
Moisuc DC; Marinca MV; Gafton B; Alexa-Stratulat T; Pavel-Tanasa M; Cianga P
Curr Oncol; 2022 May; 29(6):3996-4011. PubMed ID: 35735428
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study.
Lim AR; Kim JH; Hyun MH; Kim YH; Lee S
Support Care Cancer; 2022 Oct; 30(10):8129-8137. PubMed ID: 35779133
[TBL] [Abstract][Full Text] [Related]
6. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
Raga MG; Pérez IP; Veiga RC; Sosa MM; Aguilera MJS; Rodríguez PL; Bonastre MTT; Urtasun JA; Abad LP; Hernández IB
Clin Transl Oncol; 2023 May; 25(5):1455-1462. PubMed ID: 36723787
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Lin L; Xu JM; Wang Y; Ge FJ; Liu LJ; Zhao CH; Li SS; Liu JZ; Li ZQ
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):786-90. PubMed ID: 21163073
[TBL] [Abstract][Full Text] [Related]
10. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients.
Tamiya A; Yamazaki K; Boku N; Machida N; Kojima T; Taku K; Yasui H; Fukutomi A; Hironaka S; Onozawa Y
Int J Clin Oncol; 2009 Dec; 14(6):513-7. PubMed ID: 19967487
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Degirmenci M; Karaca B; Gorumlu G; Durusoy R; Demir Piskin G; Bozkurt MT; Cirak Y; Tunali D; Karabulut B; Sanli UA; Uslu R
Med Oncol; 2010 Sep; 27(3):585-91. PubMed ID: 19526201
[TBL] [Abstract][Full Text] [Related]
13. Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy.
Zhou YW; Long YX; Liu X; Liu JY; Qiu M
Future Oncol; 2022 Jul; 18(22):2453-2464. PubMed ID: 35712899
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
Hurwitz H; Saini S
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
[TBL] [Abstract][Full Text] [Related]
15. Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer.
Cao D; Guo CH; Liu JW; Yang X; Li Q
Tumori; 2015; 101(1):46-51. PubMed ID: 25702674
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
Tanioka H; Shimada K; Tsuji A; Kochi M; Kim HM; Takahashi T; Denda T; Takagane A; Watanabe T; Kotaka M; Nakamura M; Sunakawa YU; Takeuchi M; Ichikawa W; Fujii M
Anticancer Res; 2022 May; 42(5):2675-2681. PubMed ID: 35489740
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.
Cao Y; Tan A; Gao F; Liu L; Liao C; Mo Z
Int J Colorectal Dis; 2009 Jun; 24(6):677-85. PubMed ID: 19184059
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
19. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Fontanini G; Boni L; Galon J; Cremolini C;
Lancet Oncol; 2022 Jul; 23(7):876-887. PubMed ID: 35636444
[TBL] [Abstract][Full Text] [Related]
20. Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
Moriwaki T; Nishina T; Sakai Y; Yamamoto Y; Shimada M; Ishida H; Amagai K; Sato M; Endo S; Negoro Y; Kuramochi H; Denda T; Hatachi Y; Ikezawa K; Nakajima G; Bando Y; Tsuji A; Yamamoto Y; Morimoto M; Kobayashi K; Hyodo I
Jpn J Clin Oncol; 2022 Jul; 52(7):725-734. PubMed ID: 35470391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]